Chief Medical Officer · Elevation Oncology, Inc. (ELEV)

Valerie Jansen

A named executive officer of Elevation Oncology in every fiscal year CompBrief holds from FY2023 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$1,319,413

Salary $499,632Stock awards $193,900

FY2023: $841,810

2nd of 3 named executive officers at Elevation Oncology by FY2024 total.

3 named officers on file for Elevation Oncology, FY2024

Valerie Jansen’s pay file — $29

  • 2 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Elevation Oncology’s whole pay program stands against its peers

  • Elevation Oncology’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ELEV→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 24, 2025 (DEF 14A).

Free

Get Valerie Jansen’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Valerie Jansen compensation by year

Elevation Oncology Summary Compensation Table · all 2 fiscal years held
In US dollars, as Elevation Oncology reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023FY2024
Salary$478,958$499,632
Bonus$0$0
Stock awards$0$193,900
Option awards$150,121$419,172
Non-equity incentive$197,331$190,859
Pension and deferred compensation$0$0
All other$15,400$15,850
Total$841,810$1,319,413

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Elevation Oncology, Inc. DEF 14A filed April 24, 2025, accession 0001558370-25-005413, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Elevation Oncology, Inc. filed document, accession 0001558370-25-005413. Every figure is read from that document and cited to the page and table it appears in. Filed April 24, 2025.

$842K
$1.3M
FY23
FY24
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU70,000$39,410—
Option13,221—$3.09
Option8,334—$7.58
Option17,500—$3.78
Option70,417—$0.98
Option225,000—$2.77

Per the Outstanding Equity Awards at Fiscal Year-End table in Elevation Oncology, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Elevation Oncology’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Joseph FerraPresident and Chief Executive Officer$2,326,372
Valerie Jansen · this pageChief Medical Officer$1,319,413
David DornanChief Scientific Officer$1,165,089

The full Elevation Oncology compensation record

free company brief

This page is one person within Elevation Oncology's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Elevation Oncology's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Valerie Jansen's compensation dossier · One-time report. No refunds.